Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2009-015014-22Phase 2Completed
Phase 2, randomised, double-blind trial of fluticasone in acute rhinosinusitis (ARS) (3 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in daily major symptom score over the entire treatment period. Started Nov 2009; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2009-015014-22.